Patients Initials:

Age:

E MILIO AGUINALDO COLLEGE

School of Nursing and Midwifery

Diagnosis:

1113-1117 San Marcelino St. Ermita Manila

NAME OF DRUG
Generic Name:

CLASSIFICATION

Eryhtromycin

prevent and treat infections

bacteriostatic activity or

in many different parts of the

inhibits growth of bacteria,

body, including respiratory

Therapeutic

especially at higher

tract infections, skin

Anti- Infectivbe

concentrations,[20] but the

infections, diphtheria,

mechanism is not fully

intestinal amebiasis, acute

understood. By binding to the

pelvic inflammatory disease,

Pregnancy Risk Category

50s subunit of the bacterial

Legionnaire's disease,

70s rRNA complex, protein

pertussis, and syphilis.

Trade / Brand Name:

Patients dosage:
400 mg (ethylsuccinate) P.O.

INDICATION
Erythromycin is used to

Erythromycin displays
MACROLIDE

Erythrocin

MECHANISM OF ACTION

Pharmacologic Class

Availablility

synthesis and subsequent

Capsules (delayed-

structure and function

release): 250 mg

processes critical for life or

Tablets (enteric-coated): 250

replication are inhibited

mg, 333 mg, 500 mg

Route of Administration

Pharmacokinetics

Oral

Onset Unknown
Peak 1-4 hours
Duration Unknown

CONTRAINDICATIONS
Contraindicated in patients hypersensitive to
drug or other macrolides. Erythromycin
estolate is contraindicated in patients with
hepatic disease. Use erythromycin salts
cautiously in patients with impaired hepatic
function.
Precaution
In cardiac disease: High doses of erythromycin
may increase the chance of adverse effects in
patients with a history of an arrhythmias.
Hepatic disease :Erythromycins, especially
erythromycin estolate, may increase the
chance of adverse effects involving the liver.
Loss of hearing :

SIDE EFFECTS

Blistering, peeling, or loosening of the

skin
chills
cough
diarrhea
difficulty with swallowing
dizziness
fast heartbeat
hives or welts
joint or muscle pain
puffiness or swelling of the eyelids or
around the eyes, face, lips, or tongue
red, irritated eyes

NURSING RESPONSIBILITIES
Report onset of GI Symptoms after PO Admin
to physician
Observe for S/S of superinfection by
overgrowth of nonsusceptible bacteria or fungi
Monitor S/S of hepatotoxicity which includes:
Abdominal pain, nausea vomiting, fever,
leucocytosis and eosinophilia
Monitor ototoxicity that appears to develop
most frequently in patients receiving 4g/d or
more
Report any ototoxic effects including
dizziness, vertigo, nausea, tinnitus, hearing
impairment

ADVERSE EFFECTS
Gastrointestinal disturbances, such
as diarrhea, nausea, abdominal pain,
and vomiting, are very common
because erythromycin is
a motilin agonist